Log in to post a reply
Jul 12, 2018 02:46PM
I agree ksusan, would like to hear more on those two topics but I'm afraid that since it is still federally illegal there hasn't been much done in the way of valid studies on the use of MMJ in the US, outside of those in the industry who have a vested interest in the results. Since I live in a state where it is legal for medicinal and recreational use I've been experimenting a bit for pain and insomnia. All of my research says a minimum of 2:1 CBD to THC for pain, and that ER+ women should minimize their use of THC because it's estrogenic but I don't know if that's "real" science, much like the debate over ER+ women and soy. I'm not interested in getting high anyway (been there done that when I was kid, these days it just makes me paranoid) so I've been sticking with products with a high percentage of CBD.
What really worries me is that my 75 year old mother, who lives in a state where CBD is not legal unless one has doctor's okay for an approved condition, has been buying something called "cannabis oil" over the internet. She has no idea the percentage of THC/CBD, and if they are selling it over the internet I'm betting that it's actually hemp oil, which has an extremely low percentage of both THC and CBD (CBD typically less than 25 parts per million in hemp oil, up to 15% in true CBD oil) and any benefit she is perceives is due to a placebo effect.
There are too many companies taking advantage of people who don't know better and there's not nearly enough educational material available outside the industry itself, so buyer beware and don't waste your money on anything that doesn't clearly state the THC and CBD percentages. Thankfully here in California everything is clearly marked as to whether or not it's been tested and every product lists the amount & percentage of CBD, CBN, and THC.
IBC Stage IV de novo - mets throughout skeleton (bones & now bone marrow), liver, dozens of distant nodes, chest wall/pec muscle, skin, tumor in brachial nerves, thyroid, polycythemia from bone marrow involvement
9/8/2017, IBC, Right, Stage IV, metastasized to bone/liver/other, Grade 3, ER+/PR-, HER2+ (IHC)
9/26/2017 Taxol (paclitaxel)
2/6/2018 Perjeta (pertuzumab)
2/6/2018 Herceptin (trastuzumab)
11/26/2018 Taxol (paclitaxel)
1/30/2019 Whole-breast: Breast, Lymph nodes, Chest wall
Kadcyla (T-DM1, ado-trastuzumab)